Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Mangaceuticals Inc. (MGRX:NASDAQ), powered by AI.
Mangaceuticals Inc. is currently trading at $0.33. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Mangaceuticals Inc. on Alpha Lenz.
View Mangaceuticals Inc.'s valuation metrics on Alpha Lenz.
“Mangaceuticals Inc.'s ROE is -141.6%. Explore profitability and growth together.”
Ask for details →Mangaceuticals Inc. operates as a biotechnology company specializing in the development of plant-based pharmaceuticals. Its primary function is to harness the medicinal properties of exotic fruits and plants, particularly those with potential health benefits, to create pharmaceutical and nutraceutical products. Mangaceuticals Inc. focuses on research and innovation, employing cutting-edge biotechnological techniques to explore the therapeutic potential of natural compounds. The company's offerings have implications across multiple sectors, notably healthcare, wellness, and pharmaceuticals, as it seeks to provide natural alternatives to conventional medicines. The market significance of Mangaceuticals Inc. lies in its commitment to sustainability and the growing consumer demand for natural and holistic healthcare solutions. By integrating the principles of biotechnology and phytotherapy, the company positions itself at the forefront of a niche market segment that values environmental responsibility and health-conscious products. Mangaceuticals Inc. continues to expand its research and development capabilities, aiming to contribute to the evolving landscape of plant-based medicine and meet the needs of a health-aware global population.
“Mangaceuticals Inc.'s ROE is -141.6%. Explore profitability and growth together.”
Ask for details →Mangaceuticals Inc. (ticker: MGRX) is a company listed on NASDAQ in the Healthcare sector (Health Information Services). It has approximately 3 employees.
The current price is $0.334 with a P/E ratio of -x and P/B of -x.
ROE is -141.65% and operating margin is -4200.46%. Annual revenue is $456,021.